Protocol: CDISCPILOT01                                                                  Page  1 of 1 
Population: Efficacy 
Table 14-3.03 
ADAS Cog (11) - Change from Baseline to Week 8 - LOCF 
 
 
[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors and baseline 
value as a covariate. 
[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable. 
[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple 
comparisons. 
Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtf_eff1.sas                  21:05 Monday, June 26, 2006 
 
Placebo 
 (N=79)  
Xanomeline 
 Low Dose 
 (N=81)  
Xanomeline 
 High Dose 
 (N=74)  
Baseline 
  n                                   79 
  81 
  74 
  Mean (SD)                           24.1 (12.19) 
  24.4 (12.92) 
  21.3 (11.74) 
  Median (Range)                      21.0 (5;61) 
  21.0 (5;57) 
  18.0 (3;57) 
Week 8 
  n                                   79 
  81 
  74 
  Mean (SD)                           25.0 (13.10) 
  26.2 (12.98) 
  22.3 (12.41) 
  Median (Range)                      22.0 (5;62) 
  25.0 (5;62) 
  19.0 (2;62) 
Change from Baseline 
  n                                   79 
  81 
  74 
  Mean (SD)                            0.8 (4.81) 
   1.8 (4.14) 
   1.0 (3.62) 
  Median (Range)                       1.0 (-12;16) 
   2.0 (-12;14) 
   1.0 (-8;13) 
 
  p-value(Dose Response) [1][2]     
 
 
  0.497 
 
  p-value(Xan - Placebo) [1][3]     
 
   0.099 
   0.751 
   Diff of LS Means (SE)            
 
1.1 (0.65) 
0.2 (0.67) 
   95% CI                           
 
(-0.2;2.4) 
(-1.1;1.5) 
 
  p-value(Xan High - Xan Low) [1][3]
 
 
   0.195 
   Diff of LS Means (SE)            
 
 
-0.9 (0.66) 
   95% CI                           
 
 
(-2.2;0.4) 
 
